The project aims at translational mechanistic modeling of antibodies to predict human pharmacokinetics and target occupancy in cerebrospinal fluid

NEWS
Press-Release
June 25, 2025

InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces the extension of collaboration with discoveric bio alpha, a biotechnology company taking next generation antibody technologies into Alzheimer’s Disease.

Previously mechanistic model predicting concentration of monoclonal antibodies (mAbs) and target occupancy in cerebrospinal fluid was developed by InSysBio in collaboration with discoveric bio alpha. The further project expansion aims to use the model to support first-in-human study of NIDB-3101 leveraging cyno-to-human translation and available published clinical data as benchmarks.

Jean-Philippe Courade, CSO of discoveric bio alpha, comments on the project extension, “We were inspired to experience InSysBio’s cutting-edge mechanistic modeling approach during our first collaboration. Now we are excited to continue the project that will provide us with a range of new predictions to efficiently advance through the next stages of our antibody development”.

Oleg Demin Jr, Scientific Director, InSysBio, highlights, “We are encouraged by the opportunity to implement our expertise and solutions to further unleash the potential of the model. With its help we will support the selection of the starting dose and pharmacologically active dose to optimize first-in-human study”.

About InSysBio

InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com

About discoveric bio alpha

discoveric bio alpha is a privately owned company part of a group of three separate companies dedicated to the development of novel therapeutics for the treatment of Alzheimer’s Disease, Neuroinflammation and Antimicrobial Resistant infections. It is located in Pfäffikon, Switzerland. For more information, visit https://www.discovericbio.com/

October 2018
MoTuWeThFrSaSu
1
1. 01 Oct 2018 12:23 InSysBio Announces Continuation of Collaboration with MedImmune for Quantitative Systems Pharmacology Modeling in Systemic Lupus Erythematosus InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced today an extension of a collaboration with MedImmune, the global biologics research and development arm of AstraZeneca, for QSP modeling in systemic lupus erythematosus (SLE). The goal is to support the clinical development of anifrolumab, an investigational monoclonal antibody against the type I interferon receptor, by modeling the contributions of key cell types involved in the pathophysiology of lupus that are associated with the type I interferon dysregulation commonly seen with the disease.
2
1. 02 Oct 2018 14:05 InSysBio to present at ACoP9 InSysBio announces their participation at Ninth American Conference on Pharmacometrics (ACoP9), to be held October 7th to 10th, 2018, at the Loews Coronado Bay Resort near San Diego, CA. The theme of ACoP9 is “Modeling without Bounds”. InSysBio welcomes visitors at the booth #23.
3
4
5
6
7
8
9
1. 09 Oct 2018 15:29 InSysBio starts training course “Modeling for systems biology and biomedicine” InSysBio expert modelers Dr. Galina Lebedeva, Dr. Tatiana Karelina, Dr. Evgeny Metelkin and Dr. Oleg Demin will give the course “Modeling for systems biology and biomedicine” at the Faculty of bioengineering and bioinformatics, Lomonosov Moscow State University.
10
11
12
13
14
15
16
17
18
19
1. 19 Oct 2018 15:49 InSysBio to present at BiotechClub 2018 InSysBio announces their participation at BiotechClub 2018 conference to be held on October 26th at Hyatt Regency Moscow Petrovsky Park. The theme of BiotechClub 2018 is “From Systems Biology to Systems Medicine”.
20
21
22
23
24
1. 24 Oct 2018 13:49 InSysBio to present at ICSB 2018 InSysBio announces their participation at 19th International Conference on Systems Biology (ICSB 2018) to be held October 28th to November 1st, 2018 in Lyon, France.
25
26
27
28
29
30
31
    
Upcoming Events
07.04
InSysBio to hold a workshop on Heta at QSPC 2026
08.04
InSysBio to participate in QSPC 2026
Tags
Latest News
28.01
InSysBio to announce a new collaborative project with BeOne Medicines
29.10
InSysBio to announce its collaboration with BeOne Medicines
16.10
InSysBio to introduce a new data annotation service available in CYTOCON DB and fIVE DB
19.08
InSysBio to publish the new article "Revolutionizing drug discovery: Integrating artificial intelligence with quantitative systems pharmacology"
05.08
InSysBio to launch Immune Response Template Open for QSP modeling